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Estimation of Time Shift Models with Application to Survival




The incremental life expectancy, defined as the difference in mean survival times between two treat-
ment groups, is a crucial quantity of interest in cost-effectiveness analyses. Usually this quantity is very
difficult to estimate from censored survival data with a limited follow-up period. The paper develops
estimation procedures for a time shift survival model which, provided the model assumptions are met,
gives a reliable estimate of incremental life expectancy without extrapolation beyond the study period.
Methods for inference are developed both for individual patient data and when only published Kaplan-
Meier curves are available. Through simulation the estimators are shown to be close to unbiased and
constructed confidence intervals are shown to have close to nominal coverage for small to moderate sample
sizes.
1 Introduction
Traditionally in survival analysis, mean survival is not considered an important summary measure (Hosmer
& Lemeshow, p52) [1]. This is both because survival distributions are often heavily skewed making the
mean survival a poor summary measure, and also because determining mean survival requires knowledge, or
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assumptions, about the whole survival distribution up to some maximum time horizon. However, obtaining
estimates of mean survival is an integral part of the assessment of cost-effectiveness of health technolo-
gies. Specifically, cost-effectiveness analyses require estimation of incremental life expectancy, defined as
the difference in mean survival times between treatment groups. Most trials and studies associated with
an emerging health technology will have follow-up periods much shorter than the time horizon of inter-
est meaning conclusions about cost-effectiveness may be sensitive to the method of survival extrapolation
employed.
An approach which avoids these issues is to compare the restricted mean survival [2], which involves
computing the mean of the minimum of an individual’s survival time and a more limited time horizon,
t∗. While the restricted mean survival can be reliably estimated from right-censored data provided the
follow-up time exceeds t∗, there is no guarantee that differences in the restricted means will translate to
similar differences in the incremental life expectancy. Cost-effectiveness is usually measured on the basis
of incremental cost-effectiveness ratio (ICER) which depends upon the incremental life expectancy (or a
quality-of-life adjusted version thereof). As a consequence, cost-effectiveness analyses usually require some
degree of survival extrapolation.
Health Technology Assessments (HTA), such as those conducted by the UK’s National Institute for Health
and Care Excellence (NICE), involve building a decision-analytic model which encompasses the key events
that may occur to patients and assesses their incidence under different treatments and the associated impact
on cost, health utility and life expectancy. For tractability, a discrete-time Markov economic model is often
adopted. This requires choices regarding the range of distinct health states and also the appropriate unit of
time in the discrete time model (often referred to as the cycle length). In cancer trials or other assessments
where there is a key irreversible intermediate event, such as progression or recurrence, which drives both
quality of life and survival, a partitioned survival analysis approach is more commonly used. This involves
estimating progression-free survival and overall survival separately and determining post-progression survival
via the difference in these curves. In either type of approach it is usually necessary to make assumptions to
allow extrapolation beyond the time span of the supporting studies.
An important concurrent validity check is whether the incremental life expectancy reported by the eco-
nomic model is consistent with direct survival data from the key trial or trials. Substantial discrepancies
between model based estimates and estimates from direct data will raise questions about the appropriateness
of model assumptions or the sensitivity of the results to different forms of survival extrapolation.
Various approaches to survival extrapolation have been proposed in the literature. For instance, Latimer
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[3] proposed a model selection algorithm based on assessment of the proportional hazards assumption and
fitting a wide range of plausible parametric models to provide a sensitivity analysis to possible extrapola-
tion assumptions. Demiris et al [4] considered use of a flexible class of poly-Weibull distributions in order
to facilitate a wide range of hazard shapes including the ‘bathtub’ shaped hazards anticipated for organ
transplantation studies. Bagust and Beale [5] argued against purely data driven approaches and against
over-reliance on standard parametric models. One approach they advocate is the use of a time shift model,
previously used in HTA reviews [6, 7]. If it is anticipated that the benefits of treatment will only last for a
limited period of time it may be biologically plausible and also empirically justifiable to adopt such a model.
The model has the advantage of providing an estimate of incremental life expectancy without requiring
parametric assumptions about survival beyond the observed study period.
In this article, methodology based upon this time shift model is developed. In particular, formal estima-
tion procedures are proposed and investigated, including construction of confidence intervals. The remainder
of the article is as follows. Section 2 introduces the time shift model, Section 3 develops methods for es-
timation and construction of confidence intervals, Section 4 investigates the small sample properties of the
estimators via simulation. In Section 5, the method is illustrated by an example relating to treatments for
patients with BRAF V600E mutation melanoma. The paper concludes with a discussion.
2 Time shift models
A useful potential model for survival data in contexts where incremental life-expectancy is of interest is a
time shift model [5, 6, 7] where it is assumed that the survivor function for the group receiving the beneficial
treatment converges to a shifted version of the survivor function for the group receiving standard treatment,
after some initial period of survival benefit. We can characterize the model in terms of a time point ω, a
time shift δ < ω, an initial beneficial treatment survival curve S˜2(t), 0 ≤ t ≤ ω and the standard treatment
survival curve S1(t). It is assumed that the overall survival for the beneficial survival group is
S2(t) =

S˜2(t) if t < ω
S1(t− δ) if t ≥ ω.
For continuity it is necessary to assume S˜2(ω) = S1(ω − t). A graphical representation of this model is
given in Figure 1. The parameter ω represents the time by which all survival benefit of the new treatment
will have accrued. Initially this quantity will be assumed to be known, but estimation will be considered in
Section 3.4.
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Figure 1: Graphical representation of a time shift model with a shift of δ and convergence point ω.





Note that general shift models of the form
F2(t) = F1(t+ δ)
have wide usage in statistics, not least in the arena of quantile regression where a linear model with respect
to a particular quantile implies q = F2(tq) = F1(tq + δ) at the particular time point of interest, tq where
tq = F
−1
2 (q). However, a uniform shift model where S2(t) = S1(t+ δ) for all t > 0 is not usually appropriate
for realistic survival models as it must imply a period of time of length greater than or equal to the shift δ
in which no event is possible in the shifted group.
2.1 Estimation of incremental life-expectancy
The principal motivation for adopting a time shift model is to facilitate estimation of the incremental life
expectancy in situations where there is a clinical or biological reason to suspect that the benefits of a new
treatment will be accrued soon after commencement. The incremental life expectancy can be expressed in




{S2(t)− S1(t)} dt, (2.1)
where τ is the maximum time horizon, which could theoretically be infinity and is usually much greater than
the maximum follow-up time in available trial data.
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Note that in most standard survival models, including proportional hazards and accelerated failure time
models, in order to estimate (2.1) it is necessary to either make parametric assumptions or else have follow-up






















meaning that the incremental life-expectancy depends only on the follow-up to ω. Hence provided the
follow-up time in available trial data exceeds ω, there is scope to estimate the quantity directly without any
additional parametric assumptions. Moreover, in situations where S1(t) ≈ 1 for t < ω − δ the shift, δ, itself
can be used as a good approximation to the total incremental life expectancy.
3 Estimation of shift models
In this section methods for estimating and constructing confidence intervals for the shift parameter δ are
developed. Initially the time by which all survival benefit has accrued, ω, is assumed to be known a priori.
Note that, if the model is correctly specified, choosing any ω∗ > ω will still yield a valid estimate, but would
be expected to give less efficient estimates. Subsequently in Section 3.4 methods for an unknown ω will also
be considered.
3.1 Estimation of δ
A natural estimator of δ can be obtained simply by solving the equation
Sˆ1(ω − δ) = Sˆ2(ω) (3.1)
for δ, where Sˆj(t), j = 1, 2 is the Kaplan-Meier estimator for group j. Hence
δˆ = ω − Sˆ−11 (Sˆ2(ω)). (3.2)
Clearly we would also like to determine whether δ is significantly different from 0 or some other null value
and also obtain a 95% confidence interval for δ.
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The estimator δˆ can be defined in terms of an estimating equation
D(δ) = Hˆ2(ω)− Hˆ1(ω − δ) (3.3)
where D(δˆ) = 0 and E(D(δ)) = 0 and Hˆj(t) = − log(Sˆj(t)) is the estimated cumulative hazard function.
Through a simple application of Greenwood’s formula and the assumption of independence between the two
samples of patients an estimate of the variance of D(δ) can be obtained










where tji denotes the ith ordered failure time in group j, and dji and rji are the number of failures and
number at risk at the ith ordered event time for group j. The hypothesis test H0 : δ = δ0 against a general












where χ21(u) denotes the inverse CDF function of a χ
2
1 distribution. The performance of this construction
for realistic sample sizes will be considered via simulation in Section 4.
Superficially, it may appear that an estimator based only on matching survival at ω would be inefficient.
However, as shown in the Appendix, the estimator in (3.3) is in fact optimal among a class of estimators
based on a weighted sum of such terms, at least in the case where S2(t) has a constant hazard for t ≥ ω.








Unfortunately, while asymptotic theory for the standard error of restricted mean survival is relatively
straightforward, see for instance Andersen et al (1993) page 279 [8] , the restriction that δˆ satisfies Sˆ1(ω−δˆ) =
ˆ˜S2(ω) introduces a substantial complication. Approximate standard errors for ∆LE can be obtained through
bootstrap resampling.
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3.2 Estimation from published survival curves
In some circumstances, particularly if health economic modelling of the data involves secondary data analysis
of previously published trials, it may not be possible to access the full, individual level, survival data. Often
the data can be requested from the product sponsors, but if this is not possible then only the individual
Kaplan-Meier curves plus the counts of numbers of patients at risk at a smaller range of time points, may
be available.
Several authors have considered this issue in the context of fitting models for the purposes of meta-
analysis [9, 10, 11]. The method of Guyot et al (2012) [9] allows estimates of the full set of sufficient
statistics (numbers at risk and number of events) to be reconstructed meaning that the formulae given in
Section 3.1 can then be applied. However, it is necessary to assume that the co-ordinates of the published
survival curve can be extracted to sufficient accuracy to allow all event times can be uniquely identified.
Confidence intervals for δ based on (3.4) only require an estimate of V̂ar{D(t)}. In Appendix 2, a
method for estimating this quantity from published curves is developed, which is substantially simpler
than attempting to reconstruct the full data and only requires an assumption that Sˆ1(t) and Sˆ2(t) can be
determined for a fine grid of points, but not necessarily at all unique event times.
3.3 Goodness-of-fit and model sensitivity
A graphical check of the appropriateness of a time shift model can be obtained by calculating the optimal
shift at a range of possible time points, ω. This corresponds to the shift function, δˆ(t), considered for
general shift models [12]. If the shift model is appropriate then plotting the estimated shift as a function
of time should produce a plot that increases from time 0 until around the originally chosen ω and is then
approximately flat thereafter. Pointwise 95% confidence intervals, computed using the interval in (3.4), can
be included on the plot to aid the judgement.
If desired, and provided patient level data are available, further formal goodness-of-fit testing can be
performed based on testing whether S1(t − δˆ) = S2(t), for all t > ω. The simplest way of doing this is to
perform a log-rank test using the set of transformed survival times, t1j− (ω+ δ) and t2k−ω. Note that since
estimation of δ via (3.3) is independent of the survival beyond ω − δˆ and ω for groups 1 and 2, respectively,
the log-rank test will have its standard asymptotic distribution. Alternative tests, for instance Renyi-type
supremum tests [13], can also be used to detect deviations that are potentially non-proportional.
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3.4 Estimation with unknown ω
It may not be possible or desirable to pre-specify a suitable value of ω. Estimation of δ in such cases is more
complicated, but can still proceed through a two-step procedure based upon the estimated shift function.
Specifically the idea considered in Section 3.3 that, if a shift model is appropriate, the shift function
should increase from δˆ(0) = 0 to reach δˆ(ω) = δ0 and be constant thereafter.
Asymptotically the estimated shift at any point t is normally distributed about the true shift δ(t), where
δ(t) satisfies
S1(t− δ(t)) = S2(t)
for t > 0. This motivates the use of a weighted least-squares approach to jointly estimate δ0 and ω. In order
to proceed it is necessary to make stronger assumptions about the overall shift function than in previous
sections. Previously the relationship between S1 and S2 for t < ω was left unspecified. Since it is guaranteed
that S1(0) = S2(0), the simplest possible specification is to assume the shift increases linearly until ω implying






where t ∧ ω = min(t, ω). This specification has the advantage of not requiring any additional nuisance
parameters.
Estimation of δ0 and ω can proceed by finding the (δ0, ω) which minimize{




δˆ(t)− δ(t; δ0, ω)
}
where t = (t1, . . . , tk)
′
is a set of times at which δˆ(t) is estimated and W is a (k× k) positive-definite weight
matrix. Choice of W affects the efficiency but not consistency of the estimator. The efficient weight matrix
corresponds to the inverse of the variance-covariance matrix of δˆ(t) = (δˆ(t1), . . . , δˆ(tk))
′
. The theoretical
covariance of δˆ(t) at a pair of times (t, t′)
Var(Hˆ2(t ∧ t′)) + Var(Hˆ1(t∗ ∧ t′∗))
h1(t− δ(t))h1(t′ − δ(t′)) ,
where t∗ = t− δ(t). However, this is difficult to reliably estimate due to the dependence on hj(t). Moreover
the resulting matrix will be large and potentially ill-conditioned making inversion difficult.
A pragmatic alternative which avoids these problems while maintaining reasonable efficiency, is to use a
diagonal weight matrix with terms
Wkk =
[




where V̂ar(Hˆj(t)) is defined as in (6.3).








where Sˆ1(t) is the Kaplan-Meier estimator of survival for the control group. Standard error estimates for
ωˆ, δˆ0 and ∆ˆLE can be obtained via bootstrap resampling.
Note that there are some non-standard properties to the model. In particular, under the null where
δ0 = 0, the convergence point ω is not identifiable. Similarly if the shift function is linear or close to
linearly increasing or decreasing throughout the follow-up period then ωˆ may be unbounded. In this case, a
convention that ωˆ = tk is proposed.
4 Simulation study
In this section, the finite sample properties of the proposed estimators are investigated, both for individual
patient data and from published Kaplan-Meier estimates, using simulation.
A shift model is simulated by assuming patients in the control group have exponential survival times,
such that S1(t) = exp(−λt), while the experimental group has
S2(t) = exp[−λ{t− (t ∧ ω)/ω}].
The rate parameter λ is chosen so that mean survival in the control group is 5 years, The true value of ω is
taken to be 2 months and δ = 0.5 years (183 days). Two censoring scenarios are considered each producing
50% follow-up within one year; exponential censoring with rate log(2)/10 and uniform censoring from a
U [0, 20] distribution. Sample sizes of N = 100, 200, 500 and 1000 per group are considered.
In order to investigate the effect of misspecifying ω on the estimates of δ and the incremental life-
expectancy, ∆LE, estimates of δˆ using the estimating equation in (3.3) are obtained under four scenarios
where ω is assumed to be 2, 1.5, 3 and 4 months, respectively. In each case, ∆ˆLE is also obtained by applying
the estimator in (3.5). In addition, to investigate the properties of the estimators proposed in Section 3.4, δ
and ∆LE are also estimated assuming ω is unknown.
The results for estimates of δ are summarized in Table 1. In the scenario considered, there is evidence of
some negative bias in the estimated shift δ for small to moderate sample sizes when ω is correctly specified.
As we would expect, there is little impact on bias, but a reduction in efficiency if a larger value of ω is
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Table 1: Bias and Standard Deviation (SD) of estimates of the shift δ (measured in days) for different sample
size and censoring scenarios and different assumptions about ω.
Bias SD
N Censoring ω = 2 ω = 1.5 ω = 3 ω = 4 ωˆ ω = 2 ω = 1.5 ω = 3 ω = 4 ωˆ
100 Uniform -6.39 -50.02 -4.43 -6.81 67.47 157.99 134.02 218.18 278.59 294.91
100 Exponential 3.07 -45.55 1.52 -10.96 68.41 155.55 132.56 222.39 279.24 310.35
200 Uniform -2.15 -45.28 -2.75 -4.14 54.10 111.07 93.40 154.63 197.08 215.28
200 Exponential -2.94 -44.69 -3.44 -2.02 50.87 112.88 92.60 157.29 200.75 214.66
500 Uniform -0.78 -46.34 -2.29 1.62 32.83 69.65 58.18 97.25 124.80 125.69
500 Exponential -0.94 -45.23 0.17 -1.04 33.95 71.00 60.02 97.25 123.74 126.07
1000 Uniform 0.44 -45.72 -0.17 -0.12 16.32 50.27 42.13 67.86 87.04 81.53
1000 Exponential 0.56 -46.30 -0.42 0.63 16.92 49.89 41.69 68.60 88.57 85.96
2000 Uniform -0.27 -45.51 -0.45 -0.32 2.66 22.00 18.86 30.27 39.41 31.20
2000 Exponential 0.13 -45.64 -0.15 -0.75 2.15 22.01 18.75 30.45 39.39 31.83
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Table 2: Bias and Standard Deviation (SD) of estimates of the incremental life expectancy (∆ˆLE) (measured
in days) for different sample size and censoring scenarios and different assumptions about ω.
Bias SD
N Censoring ω = 2 ω = 1.5 ω = 3 ω = 4 ωˆ ω = 2 ω = 1.5 ω = 3 ω = 4 ωˆ
100 Uniform -5.03 -38.63 -2.32 -4.09 39.23 138.37 121.39 169.89 194.34 198.07
100 Exponential 3.40 -34.52 2.52 -5.40 38.42 136.77 120.19 173.21 194.15 203.42
200 Uniform -1.44 -34.47 -2.08 -2.81 28.66 97.83 84.94 121.12 138.09 142.34
200 Exponential -2.15 -33.94 -2.40 -0.78 27.11 99.12 84.03 123.23 140.35 142.16
500 Uniform -0.33 -35.55 -1.29 1.39 16.37 61.12 52.81 76.44 88.31 84.45
500 Exponential -0.60 -34.53 0.23 0.24 17.11 62.34 54.46 76.26 86.43 84.56
1000 Uniform 0.69 -35.05 0.06 0.32 7.85 44.23 38.25 53.37 61.30 57.06
1000 Exponential 0.64 -35.56 -0.22 0.41 7.78 43.81 37.90 53.71 62.19 59.14
2000 Uniform -0.08 -34.83 -0.23 -0.05 1.62 19.36 17.15 23.78 27.71 24.83
2000 Exponential 0.25 -34.94 0.00 -0.39 1.10 19.36 17.03 23.86 27.61 25.32
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Table 3: Empirical coverage of nominal 95% confidence intervals under different assumptions regarding
reporting of number of patients at risk assuming ω = 2 months is known.
N Censoring Cov1 Cov2 Cov3
100 Uniform 0.953 0.951 0.952
100 Exponential 0.944 0.943 0.944
200 Uniform 0.947 0.946 0.947
200 Exponential 0.952 0.952 0.952
500 Uniform 0.950 0.950 0.950
500 Exponential 0.951 0.949 0.950
1000 Uniform 0.953 0.952 0.952
1000 Exponential 0.945 0.944 0.945
2000 Uniform 0.948 0.948 0.948
2000 Exponential 0.952 0.952 0.952
chosen. Choosing too small a value of ω leads to persistent underestimation of the shift parameter. When ω
is treated as unknown there is a substantial positive bias in the estimates of δ for small to moderate sample
sizes. This is due to instances where the estimated shift function has a linear trend that persists for the
whole period of follow-up leading to positively biased estimates of ω.
For estimates of the incremental life expectancy (∆LE), given in Table 2, there is a broadly similar
pattern to the direction and magnitude of bias in the cases where ω is assumed known. However, it is
noticeable that there is less bias in ∆LE than δ when ω is treated as unknown.
Additionally, in the case where ω = 2 months is assumed known, 95% confidence intervals are constructed
using individual patient data (Cov1), the Kaplan-Meier curves plus numbers at risk every 0.5 years (Cov2)
or every 1 year (Cov3). Table 3 gives the empirical coverage of the constructed 95% confidence intervals in
each case. Confidence intervals derived from intermittently reported numbers at risk displayed very little
difference from those based on individual patient data, with the discrepancy decreasing for large sample
sizes.
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5 Example: Survival of patients melanoma with BRAF V600E
mutation
As an illustrative example, the time shift model is applied to data on patient survival in a randomized con-
trolled trial of patients with unresectable, previously untreated stage IIIc or stage IV melanoma that tested
positive for the BRAF V600E mutation. Patients were randomized to either vemurafenib or dacarbazine.
The original study demonstrated a statistically significant survival benefit in treatment by vemurafenib [14].
Subsequently, approval for use in the National Health Service in England and Wales was sought via a NICE
Single Technology Appraisal (STA). Survival follow-up in the original study was only 10 months [14], but
updated data extending this to 18 months was available for the STA. Nevertheless, in order to estimate the
mean life-years gained between treatments considerable survival extrapolation was necessary.
Survival extrapolation based on an assumption of a shared constant hazard beyond 9 months, produces
an estimated survival difference of around 3.41 months. However, the authors incorporated external evi-
dence from the dacarbazine arm of a previous trial of melanoma patients with unknown BRAF mutation
status [15] which suggested a decreasing hazard for longer term survivors treated with dacarbazine. Once
these considerations were incorporated the estimated survival difference increased around threefold, with a
corresponding improvement in cost-effectiveness.
The Evidence Review Group’s report noted that shifting the Kaplan-Meier curve of dacarbazine by
approximately 97 days, meant it lined up with the curve for vemurafenib and hence deduced that the gain
from vemurafenib was also approximately 97 days. This approach can be formalized by applying the methods
of Section 3.2 based on the data from Figure 13 of the company’s report [16], which gives the number of
patients at risk at monthly intervals. Taking the time of convergence, ω, to be 5 months gives an estimated
shift of 3.13 months (95% CI: 2.31, 3.47). Figure 2 shows the Kaplan-Meier curves with the curve for
dacarbazine shifted. There is seen to be good agreement between the shifted dacarbazine survival and the
vemurafenib survival after 5 months.
The good fit of the shift model is further confirmed through scrutiny of the shift function which remains
stable after 5 months (Figure 3).
If the length of time, ω, before benefit was accrued is not assumed known it is necessary to use the
least-squares method proposed in Section 3.4. Using this method, taking time points at 0.1 month intervals
up to 15 months gives an estimated shift of 3.22 months (95% CI: 2.17, 4.89) occurring from 4.24 months
(95% CI: 3.04, 7.17).
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Figure 2: Kaplan-Meier estimates of survival for vemurafenib and dacarbazine groups, with the estimated




























At risk (Dacarbazine) 338 305 274 242 215 191 169 150 122 101 79 62 46 31 22 15
At risk (Vemurafenib) 337 336 335 326 313 299 280 259 245 223 181 147 112 86 54 35
Figure 3: Estimated shift function with pointwise 95% confidence limits for the BRAF V600E mutation
data. Bold dashed line represents the estimated shift assuming an unknown ω.














The incremental survival, ∆ˆLE, obtained using (3.5) is estimated as 3.04 months (95% CI: 2.44, 3.63) if
ω = 5 is assumed known and 3.17 months (95% CI: 2.21, 4.54) if ω is estimated from the data.
The time shift model fits the available direct trial data very closely. In addition, unlike other models
which could be applied, it produces an incremental life expectancy estimate that is independent of particular
assumptions about the shape of the long-term hazard in the dacarbazine arm. In particular, it is still
consistent with the possibility of a long-term decreasing hazard for both groups. In the absence of information
about long-term survival, the assumption used in the time shift model that the hazards in the two treatment
arms are the same up to the specified fixed shift cannot be empirically tested. Therefore a definitive estimate
of the difference in mean survival between treatments cannot be obtained. However, the estimate from the
shift-model does raise considerable doubt about the credence of more favourable estimates based on other
methods which also required, potentially stronger, untestable assumptions about long-term survival.
6 Discussion
The time shift model is useful in situations where it is expected that the benefits of a treatment will be
short-term. It is straightforward to efficiently estimate the shift and obtain valid 95% confidence intervals.
Good statistical properties can be demonstrated if ω can be pre-specified in advance. There is also scope to
jointly estimate ω and δ from the data, but much larger sample sizes are required to ensure estimates are
close to unbiased.
A limitation of the time shift model is that it does not give a direct estimate of the mean survival in
each individual treatment group. Moreover, it does not fully indicate at what time points the difference
in mean survival is accrued. This restricts the direct use for cost-effectiveness analysis, where some form
of discounting is usually applied, meaning survival accrued far in the future is given lower weighting. For
these quantities it is still necessary to make some assumptions about the form of S1(t) beyond the range
of the data. In practice, the majority of the benefit occurs by time ω and within the follow-up period,
making the results relatively insensitive to any sensible choice for the long-term hazard. The restriction that
S1(t− δ) = S2(t) can also be built into a more general decision-analytic model.
The shift-model should be considered as a possible approach to survival extrapolation in an HTA, but
only if it is biologically plausible and there is empirical evidence of its appropriateness. Assuming biological
plausibility, a practical strategy would be to first scrutinize the shift-function; if this shows evidence of
the characteristic flattening required then we would proceed to formally estimate the shift model using the
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methods in Section 3. If there is no evidence of convergence then alternative extrapolation methods, such as
fitting exponential or other parametric models to the tails of the respective survival curves on the basis of
the trend in the cumulative hazard functions [5], should be used. Such an approach should yield estimates
of incremental life expectancy that are less prone to bias than the procedure used in Section 4 where the
shift-model was applied regardless of evidence of a convergence point within the follow-up period. However,
fully formalizing this approach and therefore assessing its statistical properties requires additional work.
In the BRAF V600E example considered, the shift model represents a very good fit to the data. Sub-
sequent clinical experience also seems to have confirmed its appropriateness, with acknowledgement that
most patients develop a resistance to vemurafenib within 6-7 months [17]. Similarly, in the application of
the model in an STA relating to non-small-cell lung cancer the apparent time-shift observed in the overall
survival was supported by additional information on post-progression survival requested by the Evidence
Review Group which revealed the new treatment provided no post-progression survival benefit [7].
In other situations, even if the underlying process does broadly adhere to such a pattern and even if
the sample size of the study is reasonably large, there may be variation away from this pattern particularly
towards the end of the follow-up period. The necessity to have empirical justification for the shift model is
likely to preclude its use in studies with small sample sizes. The simulation results suggests that the approach
should be avoided or the estimates viewed with caution for data with less than 200 patients per treatment
group. In such cases it may be safer to fix a conservatively large ω, rather than attempt to estimate it, in
order to limit the possibility of bias.
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Appendix 1: Efficiency of the estimator for δ
In this appendix it is shown that the shift estimator based on the estimating equation in (3.3) is the most
efficient amongst a class of weighted estimators in the case where the hazard functions are constant after
time ω.
The estimating equation in (3.3) can be extended to a case where δ is chosen based on the weighted






Hˆ2(tj)− Hˆ1(tj − δ)
}
, (6.1)
for some weight function w(t) ≥ 0. The asymptotic variance of an estimator δˆ satisfying D∗(δ) = 0 is given
by Var(D∗(δ0))/E(
∂D¯(δ0)
∂δ ) where D¯(δ) is (6.1) with Hˆj(t) replaced by Hj(t) for j = 1, 2 and δ0 is the true
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shift. It is convenient to note that D∗(δ) can be rewritten in terms of increments of the estimated cumulative










k=j w(tj), ∆Hˆk(t1) = Hˆk(t1) and ∆Hˆk(tj) = Hˆk(tj) − Hˆk(tj−1) for j > 1. Under this

















w∗(tj) {h2(tj)− h2(tj−1)} . (6.2)
In the case where the hazard function h2(t) is constant beyond ω, all the terms in the summation in (6.2)
are equal to zero. It therefore follows that minimizing Var(δˆ) is achieved by setting w∗(tj) = 0 for j > 1. In
addition, since Var(Hˆj(t)) are increasing functions in t, it follows that the most efficient consistent estimate
is achieved when tj = ω. In other situations it may be possible to get slightly more efficient estimators
through judicious use of weighting, but this would require knowledge of the shape of the hazard function
and also the censoring distributions.
Appendix 2: Estimation of Var(D(δ)) from published survival curves
In this section, a simplified method for obtaining an estimate of Var(D(δ)) from published survival curves
is developed.
It is assumed that Sˆj(t) is known at a set of points {tjl, l = 1, . . . , L} but, unlike the approach of Guyot
et al [9], these do not necessarily coincide with the exact set of event times. In addition it is assumed that
the number of patients at risk in group j, Rj(t), is known at a set of points {ujk, k = 1, . . . ,K}, which is a
subset of {tjl, l = 1, . . . , L}.
For mathematical convenience it is assumed that the number of events at any event time is small compared










It is then assumed that the hazard function hj(t) is piecewise constant between consecutive evaluation
times tl−1j , tlj and that the censoring hazard gj(t) is constant between consecutive evaluation times of the
number at risk, uk−1j , ukj .
A natural estimator for hlj , the constant hazard assumed between times tl−1j and tlj is then
log{Sˆj(tl−1j)} − log{Sˆj(tlj)}
tlj − tl−1j .
Similarly since Rj(t) = Rj(0)Sj(t)Gj(t) where Gj(t) is the survivor function of the censoring distribution, a
natural estimator for gkj , the constant censoring hazard assumed between times, uk−1j and ukj is then
log{Sˆj(uk−1j)Rj(uk)} − log{Sˆj(ukj)Rj(uk−1j)}
ukj − uk−1j .







gkj(min(ukj , tlj)− uk−1j)
 ,
which is the survivor function resulting from the estimated piecewise constant censoring hazards.










exp{(g∗lj + hlj)(tlj − tl−1j)} − 1
]
Rˆj(tl−1)(g∗lj + hlj)
where g∗lj = gk∗j where k
∗ is the unique k satisfying uk−1j ≤ tlj < ukj .
The estimate for Var{D(d)} to be used in (3.4) is then
V̂ar{D(d)} =
∑
i:t2i≤ω
Iˆ2i −
∑
i:t2i≤ω−d
Iˆ1i.
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